^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Yescarta (axicabtagene ciloleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma
